News & Resources
Read the latest updates and download public-facing resources from Americans for Safe and Effective Medicines.
Latest News
-
Why We Created ASEM — And Why Now
Most people have never heard of pharmaceutical compounding. But if you’ve been following the surge in GLP-1 weight-loss medications, you’ve almost certainly encountered it — whether you knew it or not. Real compounding has a legitimate place in medicine: a licensed pharmacist, working from a valid prescription, prepares a customized medication for one patient when…
Press Releases & Statements
-
A Statement on Needed Reforms to Protect Patient Safety from Fred H. Mills Jr., PharmD – ASEM Chief Policy Officer
“As a compounding pharmacist for nearly 50 years, I know the importance of legitimate, patient-specific compounding. I also know that there is a fundamental difference between the compounding that ensures a cancer patient has the right treatment dosage versus the mass compounding of GLP-1s today – unvetted additives, no batch consistency, telehealth distribution by faux-pharmacists,…
-
Americans for Safe and Effective Medicines Launches
Americans for Safe and Effective Medicines (ASEM) today launched as a new national advocacy organization dedicated to protecting patients from illegal mass compounding, counterfeit products, and misleading marketing practices and holding bad actors accountable…
Resources
National Surveys
Consumers’ & Physicians’ View of Mass Compounding, May 2026
84% of consumers say FDA approval matters. Half of current GLP-1 users mistakenly believe compounded versions have it — and physicians are seeing the same confusion in their exam rooms. A one-page summary of ASEM’s consumer and physician survey findings.
DownloadReport
The Shortage is Over. The Risks Are Not. How Illegal Mass Compounding Is Undermining Patient Safety—And What Must Happen Next
ASEM’s report on how illegal mass compounding is undermining patient safety — and what must happen next.
View ReportPolicy Brief
The Concise Case for Reform
Key findings and recommendations from ASEM’s report on illegal mass compounding — unsafe practices, illicit supply chains, and the misleading marketing keeping patients in the dark.
View Policy Brief